Peptide-Based Monoclonal Antibody Production Against SAG1 (P30) Protein of<i>Toxoplasma gondii</i>

Vishteh, Mohadeseh Naghi; Mamaghani, Amirreza Javadi; Rashidi, Sama; Tabaei, Seyyed Javad Seyyed; Jeddi‐Tehrani, Mahmood

doi:10.1089/mab.2019.0041

Cited by 7 publications

(6 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A number of different toxoplasma antigens have been proposed in the last years as candidates for the development of monoclonal antibodies or vaccines, although only preliminary studies have been performed so far. These include rhoptry kinase 18 of Toxoplasma gondii (TgROP18), a key virulence factor that promotes parasite proliferation for which species- and strain-specific mAbs have been obtained ( 113 ), and a synthetic peptide from surface antigen 1 (SAG1) ( 114 ).…”

Section: Toxoplasmosismentioning

confidence: 99%

Monoclonal Antibodies for Protozoan Infections: A Future Reality or a Utopic Idea?

et al. 2021

View full text Add to dashboard Cite

Following the SARS-CoV-2 pandemic, several clinical trials have been approved for the investigation of the possible use of mAbs, supporting the potential of this technology as a therapeutic approach for infectious diseases. The first monoclonal antibody (mAb), Muromonab CD3, was introduced for the prevention of kidney transplant rejection more than 30 years ago; since then more than 100 mAbs have been approved for therapeutic purposes. Nonetheless, only four mAbs are currently employed for infectious diseases: Palivizumab, for the prevention of respiratory syncytial virus (RSV) infections, Raxibacumab and Obiltoxaximab, for the prophylaxis and treatment against anthrax toxin and Bezlotoxumab, for the prevention of Clostridium difficile recurrence. Protozoan infections are often neglected diseases for which effective and safe chemotherapies are generally missing. In this context, drug resistance and drug toxicity are two crucial problems. The recent advances in bioinformatics, parasite genomics, and biochemistry methodologies are contributing to better understand parasite biology, which is essential to guide the development of new therapies. In this review, we present the efforts that are being made in the evaluation of mAbs for the prevention or treatment of leishmaniasis, Chagas disease, malaria, and toxoplasmosis. Particular emphasis will be placed on the potential strengths and weaknesses of biological treatments in the control of these protozoan diseases that are still affecting hundreds of thousands of people worldwide.

show abstract

Section: Toxoplasmosismentioning

confidence: 99%

Monoclonal Antibodies for Protozoan Infections: A Future Reality or a Utopic Idea?

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The main antigens of the T. gondii are membrane, cytoplasmic, and soluble antigens that the latter results from a combination of cytoplasmic shedding, active secretion by the parasite, and lysis due to the immune system responses [ 16 ]. The parasite secretory antigens that are produced by three parasite’s organelles microneme, rhoptry, and dense granule comprise 90% of the soluble antigens [ 17 , 18 ]. The T. gondii DNA vaccine studies are mainly focused on four families of molecules.…”

Section: Introductionmentioning

confidence: 99%

Toxoplasma gondii vaccine candidates: a concise review

et al. 2022

View full text Add to dashboard Cite

Toxoplasma gondii is an obligate intracellular parasite that causes toxoplasmosis. It has been shown that the severity of symptoms depends on the functioning of the host immune system. Although T. gondii infection typically does not lead to severe disease in healthy people and after infection, it induces a stable immunity, but it can contribute to severe and even lethal Toxoplasmosis in immunocompromised individuals (AIDS, bone marrow transplant and neoplasia). The antigens that have been proposed to be used in vaccine candidate in various studies include surface antigens and secretory excretions that have been synthesized and evaluated in different studies. In some studies, secretory antigens play an important role in stimulating the host immune response. Various antigens such as SAG, GRA, ROP, ROM, and MAG have been from different strains of T. gondii have been synthesized and their protective effects have been evaluated in animal models in different vaccine platforms including recombinant antigens, nanoparticles, and DNA vaccine. Four bibliographic databases including Science Direct, PubMed Central (PMC), Scopus, and Google Scholar were searched for articles published up to 2020.The current review article focuses on recent studies on the use and usefulness of recombinant antigens, nanoparticles, and DNA vaccines.

show abstract

“…Many T. gondii proteins are mainly secreted outside through three specific organelles (rhoptry, dense granule, and microneme), some of which could well activate the host immune system. T. gondii surface antigen 1 (SAG1), as a highly immunogenic protein, is mainly distributed on the tachyzoite surface by glycosyl-phosphatidylinositol anchoring [25,26]. Dense granule proteins 1 and 4 (GRA1 and GRA4) secreted by T. gondii have good antigenicity [27][28][29][30].…”

Section: Introductionmentioning

confidence: 99%

Characterization and evaluation of a recombinant multiepitope peptide antigen MAG in the serological diagnosis of Toxoplasma gondii infection in pigs

et al. 2021

View full text Add to dashboard Cite

Background Toxoplasmosis caused by Toxoplasma gondii is a serious disease threatening human and animal health. People can be infected with T. gondii by ingesting raw pork contaminated with cysts or oocysts. Serological test is a sensitive and specific method usually used for large-scale diagnosis of T. gondii infection in humans and animals (such as pigs). Commercial pig Toxoplasma antibody ELISA diagnostic kits are expensive, which limits their use; moreover, the wide antigen composition used in these diagnostic kits is still unclear and difficult to standardize. The multiepitope peptide antigen is a novel diagnostic marker, and it has potential to be developed into more accurate and inexpensive diagnostic kits. Methods The synthetic multiepitope antigen (MAG) cDNA encoding a protein with epitopes from five T. gondii-dominant antigens (SAG1, GRA1, ROP2, GRA4, and MIC3) was designed, synthesized, and expressed in Escherichia coli BL21 (DE3) strain. The recombinant protein was detected through western blot with pig anti-T. gondii-positive and -negative serum, and then IgG enzyme-linked immunosorbent assay (ELISA) named MAG-ELISA was designed. The MAG-ELISA was evaluated in terms of specificity, sensitivity, and stability. The MAG-ELISA was also compared with a commercial PrioCHECK®Toxoplasma Ab porcine ELISA (PrioCHECK ELISA). Finally, the trend of pig anti-T. gondii IgG levels after artificial infection with RH tachyzoites was evaluated using MAG-ELISA and two other ELISA methods (rMIC3-ELISA and PrioCHECK ELISA). Results MAG antigen could be specifically recognized by pig anti-T. gondii-positive but not -negative serum. MAG-ELISA showed high diagnostic performance in terms of specificity (88.6%) and sensitivity (79.1%). MAG-ELISA could be used for detecting anti-T. gondii IgG in the early stage of T. gondii infection in pigs (at least 7 days after artificial infection). Conclusions Our results suggest that MAG antigen can be applied to specifically recognize anti-T. gondii IgG in pig, and MAG-ELISA has the potential for large-scale screening tests of T. gondii infection in pig farms and intensive industries. Graphical abstract

show abstract

Peptide-Based Monoclonal Antibody Production Against SAG1 (P30) Protein ofToxoplasma gondii

Cited by 7 publications

References 39 publications

Monoclonal Antibodies for Protozoan Infections: A Future Reality or a Utopic Idea?

Monoclonal Antibodies for Protozoan Infections: A Future Reality or a Utopic Idea?

Toxoplasma gondii vaccine candidates: a concise review

Characterization and evaluation of a recombinant multiepitope peptide antigen MAG in the serological diagnosis of Toxoplasma gondii infection in pigs

Contact Info

Product

Resources

About